GC
ATRS

Guggenheim Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Guggenheim Capital’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-530,246
Closed -$1.17M – 2689
2018
Q1 		$1.17M Sell
530,246
-100,803
-16% -$227K ﹤0.01% 1997
2017
Q4 		$1.25M Buy
631,049
+222,105
+54% +$483K ﹤0.01% 1961
2017
Q3 		$1.33M Buy
408,944
+4,969
+1% +$15.3K ﹤0.01% 1924
2017
Q2 		$1.3M Buy
+403,975
New +$1.14M ﹤0.01% 1915
2016
Q1 		– Sell
-15,635
Closed -$19K – 3016
2015
Q4 		$19K Buy
15,635
+4,931
+46% +$6.86K ﹤0.01% 2922
2015
Q3 		$18K Sell
10,704
-5,247
-33% -$10.3K ﹤0.01% 2900
2015
Q2 		$33K Buy
15,951
+3,266
+26% +$7.92K ﹤0.01% 2976
2015
Q1 		$34K Buy
12,685
+783
+7% +$1.99K ﹤0.01% 2963
2014
Q4 		$31K Buy
+11,902
New +$26.7K ﹤0.01% 2950
2014
Q3 		– Sell
-10,492
Closed -$28K – 3162
2014
Q2 		$28K Buy
+10,492
New +$31.6K ﹤0.01% 3143
2014
Q1 		– Sell
-11,481
Closed -$51K – 3383
2013
Q4 		$51K Buy
11,481
+688
+6% +$2.8K ﹤0.01% 3054
2013
Q3 		$44K Buy
10,793
+716
+7% +$3.13K ﹤0.01% 2949
2013
Q2 		$42K Buy
+10,077
New +$38.9K ﹤0.01% 2925

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital's ATRS Position: Q2 2018 in Review

Guggenheim Capital sold out of Antares Pharma, Inc. (ATRS) in Q2 2018, closing a stake of 530,246 shares — an estimated $1.17M sold.

Guggenheim Capital first reported a position in ATRS in Q2 2013 and held it in 13 quarters. The position peaked at $1.33M in Q3 2017. 101 funds tracked by Wall St. Rank hold ATRS as of Q2 2018.

  • Guggenheim Capital reported no remaining Antares Pharma, Inc. position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 530,246 Antares Pharma, Inc. shares in Q2 2018, an estimated $1.17M.
  • Guggenheim Capital first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 13 quarters.
  • Guggenheim Capital's Antares Pharma, Inc. position peaked at $1.33M in Q3 2017.
  • 101 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.